This is a preview of subscription content, log in via an institution to check access.
Notes
2018 British pounds
Reference
Ramos M, et al. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes Therapy : 10 Oct 2019. Available from: URL: https://doi.org/10.1007/s13300-019-00701-3
Rights and permissions
About this article
Cite this article
Empagliflozin cost effective versus sitagliptin and saxagliptin. PharmacoEcon Outcomes News 839, 16 (2019). https://doi.org/10.1007/s40274-019-6297-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6297-4